X4 Pharmaceuticals, Inc.
- XFOR
- NASDAQ
- Biotechnology
- Rare Disease Therapeutics
- CXCR4 Antagonist (WHIM Syndrome)
$2.59
Today −1.89%Quote Oct 16, 2026, 08:00 PM UTC
−26.00%over the last month
Max drawdown −31.6%From 1-month high −27.7%3 months −29.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$256.8M
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$11.50
+344.0% from here
Floor
$2.48
4.2% below price
Where the price sits
13 analysts
Analyst range, low to high
$11.00$12.00
- Price $2.59
- Resistance $2.75
- Consensus $11.50
Analysts' average target sits about 344% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about XFORPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $8.8M
- License and Other Revenue$6.4M73.1%
- Product$2.4M26.9%
Industry
Biotechnology
Employees
45